Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC). (December 2016) - Tijeras-Raballand, A.; Le Bitoux, M.A.; Maillard, A.; Albuquerque, M.; Colnot, N.; Barral, M.; Dohan, A.; Bonnin, P.; Pocard, M.; Benhadji, K.; Paradis, V.; Raymond, E.; et al.